ALS News Today

Masitinib trial insurance offers a safety net for ALS research

Masitinib is an experimental oral therapy for ALS that's aimed at slowing disease progression. AB Science secured insurance ...

AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients

PRESS RELEASEAB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV DEMONSTRATING SUBSTANTIAL SURVIVAL BENEFITS AND PRESERVED QUALITY OF LIFE WITH ...
Seeking Alpha

AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS

AB Science SA (Euronext - FR0010557264 - AB) today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in ...
ksn.com

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

AB Science SA (Euronext - FR0010557264 - AB) today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis (ALS), study AB23005, has been authorized by the first ...
Hosted on MSN

AB Science Reports Key Developments and Financial Results

Ab Science ( (ABSCF)) has released its Q2 earnings. Here is a breakdown of the information Ab Science presented to its investors. Take advantage of TipRanks Premium at 50% off! Unlock powerful ...